RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response.
Allergy
; 77(9): 2848-2852, 2022 09.
Article
in En
| MEDLINE
| ID: mdl-35595723
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pulmonary Eosinophilia
/
Asthma
/
Anti-Asthmatic Agents
Limits:
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Allergy
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: